Complex Psychopharmacology

September, 2007 | Vol: 5 Issue: 9

In this issue


Combining Meds for Depression: The State of The Art

In surveys, it’s clear that most psychiatrists practice as unimaginatively as I typically do, meaning that their drug of first choice for most depressed patients is an SSRI (Petersen T, et al., Prog Neuropsychopharmacol Biol Psychiatry 2002; 26:177-187). If SSRIs don’t work, there are various options. Optimization, or raising the dose, is one option, and is covered in another article in this issue. Many of us will eventually move on to a combination/augmentation strategy. But it's becoming increasingly difficult to know which combinations to use. The evidence becomes murkier with each new study. Here’s a brief, selective run-down of the state of the art.

Dosing Psychotropics: How High Can We Go?

How high can we safely dose common psychotropics? Given the poor performance of medication combinations in recent studies, it’s time for a close look at the safety and efficacy of raising doses, sometimes known as “dose optimization.”

Expert QA

Research Update